| Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ... Neurology 89 (1), 88-100, 2017 | 3374 | 2017 |
| Vascular dementia J T O'Brien, A Thomas The Lancet 386 (10004), 1698-1706, 2015 | 1119 | 2015 |
| Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology GM Goodwin, ... Journal of Psychopharmacology 23 (4), 346-388, 2009 | 648 | 2009 |
| Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial S Banerjee, J Hellier, M Dewey, R Romeo, C Ballard, R Baldwin, ... The Lancet 378 (9789), 403-411, 2011 | 594 | 2011 |
| Depression and dementia: cause, consequence or coincidence? S Bennett, AJ Thomas Maturitas 79 (2), 184-190, 2014 | 559 | 2014 |
| Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis T Wise, J Radua, E Via, N Cardoner, O Abe, TM Adams, F Amico, ... Molecular psychiatry 22 (10), 1455-1463, 2017 | 528 | 2017 |
| Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study AJ Thomas, JT O'Brien, S Davis, C Ballard, R Barber, RN Kalaria, ... Archives of general psychiatry 59 (9), 785-792, 2002 | 463 | 2002 |
| Research criteria for the diagnosis of prodromal dementia with Lewy bodies IG McKeith, TJ Ferman, AJ Thomas, F Blanc, BF Boeve, H Fujishiro, ... Neurology 94 (17), 743-755, 2020 | 444 | 2020 |
| Increase in interleukin-1β in late-life depression AJ Thomas, S Davis, C Morris, E Jackson, R Harrison, JT O’Brien American Journal of Psychiatry 162 (1), 175-177, 2005 | 402 | 2005 |
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial C Ballard, M Margallo-Lana, E Juszczak, S Douglas, A Swann, A Thomas, ... Bmj 330 (7496), 874, 2005 | 398 | 2005 |
| Depression and vascular disease: what is the relationship? AJ Thomas, RN Kalaria, J T O’Brien Journal of affective disorders 79 (1-3), 81-95, 2004 | 388 | 2004 |
| Frontotemporal dementia and its subtypes: a genome-wide association study R Ferrari, DG Hernandez, MA Nalls, JD Rohrer, A Ramasamy, JBJ Kwok, ... The Lancet Neurology 13 (7), 686-699, 2014 | 373 | 2014 |
| Dementia with Lewy bodies: an update and outlook TF Outeiro, DJ Koss, D Erskine, L Walker, M Kurzawa-Akanbi, D Burn, ... Molecular neurodegeneration 14, 1-18, 2019 | 314 | 2019 |
| Pharmacological management of Lewy body dementia: a systematic review and meta-analysis C Stinton, I McKeith, JP Taylor, L Lafortune, E Mioshi, E Mak, ... American Journal of Psychiatry 172 (8), 731-742, 2015 | 295 | 2015 |
| Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors LM Allan, EN Rowan, MJ Firbank, AJ Thomas, SW Parry, TM Polvikoski, ... Brain 134 (12), 3716-3727, 2011 | 266 | 2011 |
| New evidence on the management of Lewy body dementia JP Taylor, IG McKeith, DJ Burn, BF Boeve, D Weintraub, C Bamford, ... The Lancet Neurology 19 (2), 157-169, 2020 | 244 | 2020 |
| Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross‐sectional comparative study DJ Burn, EN Rowan, T Minett, J Sanders, P Myint, J Richardson, ... Movement disorders: official journal of the Movement Disorder Society 18 (8 …, 2003 | 240 | 2003 |
| Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease KE McAleese, L Walker, S Graham, ELJ Moya, M Johnson, D Erskine, ... Acta neuropathologica 134, 459-473, 2017 | 236 | 2017 |
| Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology JT O’brien, A Burns Journal of Psychopharmacology 25 (8), 997-1019, 2011 | 235 | 2011 |
| Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology JT O’Brien, C Holmes, M Jones, R Jones, G Livingston, I McKeith, P Mittler, ... Journal of Psychopharmacology 31 (2), 147-168, 2017 | 227 | 2017 |
John Paul TaylorNewcastle UniversityVerified email at ncl.ac.uk
